Cepheid (CPHD) Releases FY13 Earnings Guidance
Cepheid (NASDAQ:CPHD) issued an update on its FY13 earnings guidance on Thursday morning. The company provided earnings per share (EPS) guidance of $0.22-$0.24 for the period, compared to the Thomson Reuters consensus estimate of $0.19, ARN reports. The company issued revenue guidance of $389-$391 million, compared to the consensus revenue estimate of $383.47 million.
A number of research firms have recently commented on CPHD. Analysts at SunTrust initiated coverage on shares of Cepheid in a research note to investors on Thursday, October 10th. They set a neutral rating on the stock. On a related note, analysts at Wedbush raised their price target on shares of Cepheid from $37.00 to $42.00 in a research note to investors on Thursday, October 3rd. They now have an outperform rating on the stock. Finally, analysts at Merrill Lynch downgraded shares of Cepheid from a buy rating to a neutral rating in a research note to investors on Tuesday, October 1st. Three analysts have rated the stock with a sell rating, eight have assigned a hold rating and eleven have given a buy rating to the stock. Cepheid presently has an average rating of Hold and an average price target of $40.53.
Shares of Cepheid (NASDAQ:CPHD) traded up 1.13% during mid-day trading on Thursday, hitting $38.47. The stock had a trading volume of 608,545 shares. Cepheid has a one year low of $28.12 and a one year high of $40.31. The stock has a 50-day moving average of $38.06 and a 200-day moving average of $36.54. The company’s market cap is $2.595 billion.
Cepheid (NASDAQ:CPHD) last posted its quarterly earnings results on Thursday, October 17th. The company reported ($0.20) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by $0.09. The company had revenue of $100.10 million for the quarter, compared to the consensus estimate of $93.70 million. During the same quarter in the prior year, the company posted ($0.32) earnings per share. The company’s quarterly revenue was up 25.6% on a year-over-year basis. Analysts expect that Cepheid will post $-0.26 EPS for the current fiscal year.
Cepheid is a molecular diagnostics company that develops, manufactures and markets fully-integrated systems for testing in the Clinical market, as well as for application in its legacy Non-Clinical market.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.